Mirabella Financial Services LLP bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,700,000 shares of the company's stock, valued at approximately $15,392,000. MaxCyte makes up 1.4% of Mirabella Financial Services LLP's investment portfolio, making the stock its 12th biggest holding. Mirabella Financial Services LLP owned 3.50% of MaxCyte as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of MXCT. State Street Corp increased its position in MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company's stock worth $8,827,000 after purchasing an additional 111,066 shares in the last quarter. Barclays PLC increased its holdings in shares of MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after buying an additional 127,156 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of MaxCyte by 2.0% during the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock worth $9,628,000 after buying an additional 47,960 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of MaxCyte in the 3rd quarter valued at $260,000. Finally, SG Americas Securities LLC boosted its holdings in shares of MaxCyte by 25.9% during the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company's stock valued at $199,000 after acquiring an additional 9,836 shares in the last quarter. Institutional investors own 68.81% of the company's stock.
MaxCyte Price Performance
Shares of MXCT stock traded up $0.02 on Friday, reaching $2.86. 155,082 shares of the company were exchanged, compared to its average volume of 532,533. The company has a 50-day moving average of $3.04 and a 200-day moving average of $3.70. The company has a market cap of $303.63 million, a price-to-earnings ratio of -8.43 and a beta of 1.39. MaxCyte, Inc. has a one year low of $2.21 and a one year high of $5.26.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on MXCT shares. Stifel Nicolaus lowered their price objective on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th.
Check Out Our Latest Report on MXCT
About MaxCyte
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
